STOCK TITAN

Rallybio Corporation - RLYB STOCK NEWS

Welcome to our dedicated page for Rallybio Corporation news (Ticker: RLYB), a resource for investors and traders seeking the latest updates and insights on Rallybio Corporation stock.

Rallybio Corporation Common Stock (Symbol: RLYB) is a clinical-stage biotechnology company founded in January 2018 and based in Farmington, CT at the University of Connecticut’s Technology Incubation Program. The company is dedicated to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Rallybio’s founders and team members boast a notable track record in pharmaceutical research and development, effectively leveraging their expertise to pursue promising drug candidates.

Rallybio’s core focus lies in developing treatments that target severe and often devastating diseases. Among its key projects is a program aimed at preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare and potentially life-threatening condition that can cause uncontrolled bleeding in fetuses and newborns. This program exemplifies Rallybio’s commitment to tackling unmet medical needs through innovative solutions.

The company’s approach involves working on drug candidates with strong biological rationales, utilizing well-validated therapeutic modalities such as small molecules, engineered proteins, and antibodies. By prioritizing robust clinical and commercial filters, Rallybio ensures that only the most promising assets are advanced through the development pipeline.

Recent achievements and ongoing projects highlight Rallybio’s progress and potential in the biotechnology sector. The company continues to build strategic partnerships and collaborations, enhancing its capabilities and resources for drug development. Financially, Rallybio remains focused on securing the necessary funding to support its ambitious research and development goals.

For investors and stakeholders, Rallybio Corporation represents a forward-thinking entity with a clear mission to improve patient outcomes through groundbreaking therapies. The company’s strategic location within a renowned technology incubation program underscores its innovative spirit and commitment to cutting-edge research.

Rhea-AI Summary
Rallybio Corporation (Nasdaq: RLYB) announces participation in investor conferences, including Stifel 2023 Healthcare Conference and 6th Annual Evercore ISI HealthCONx Conference. CEO Steve Uden, M.D. to present corporate overview and participate in fireside chat. Live webcasts and replays available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.79%
Tags
conferences
-
Rhea-AI Summary
Rallybio Corporation (Nasdaq: RLYB) announced that their abstract for the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study has been accepted for poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting. The presentation will focus on identifying pregnancies at higher risk for HPA-1a Alloimmunization and FNAIT. The abstract can be accessed on the ASH Annual Meeting website and the poster will be available on Rallybio's website after the presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
none
-
Rhea-AI Summary
Rallybio CEO to participate in panel discussion at healthcare summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.14%
Tags
conferences
Rhea-AI Summary
Rallybio presents positive clinical data for RLYB116, demonstrating reduction in free C5 concentrations and no serious adverse events. Phase 1 multiple ascending dose study ongoing, with preliminary data expected in 4Q 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Rallybio Corporation to participate in upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.66%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.08%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.57%
Tags
management

FAQ

What is the current stock price of Rallybio Corporation (RLYB)?

The current stock price of Rallybio Corporation (RLYB) is $0.95 as of December 20, 2024.

What is the market cap of Rallybio Corporation (RLYB)?

The market cap of Rallybio Corporation (RLYB) is approximately 41.5M.

What does Rallybio Corporation do?

Rallybio Corporation is a biotechnology company dedicated to developing life-transforming therapies for severe and rare disorders.

When was Rallybio Corporation founded?

Rallybio Corporation was founded in January 2018.

Where is Rallybio Corporation located?

Rallybio Corporation is based in Farmington, CT, at the University of Connecticut’s Technology Incubation Program.

What is Rallybio's key research focus?

Rallybio focuses on developing treatments for severe and rare diseases, including a program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

What are some of the therapeutic modalities used by Rallybio?

Rallybio uses well-validated therapeutic modalities such as small molecules, engineered proteins, and antibodies.

Who founded Rallybio Corporation?

Rallybio was founded by seasoned leaders from the biopharma industry with extensive experience in research, development, and finance.

How does Rallybio select its drug candidates?

Rallybio uses a series of robust clinical and commercial filters to evaluate and select highly promising drug candidates.

What makes Rallybio's approach unique?

Rallybio combines a strong biological rationale with well-validated therapeutic modalities to address severe and rare diseases.

Is Rallybio a publicly traded company?

Rallybio Corporation is a private, early-stage biotechnology company.

What recent achievements has Rallybio made?

Rallybio has made significant progress in its research and development programs, established strategic partnerships, and secured funding to support its goals.

Rallybio Corporation

Nasdaq:RLYB

RLYB Rankings

RLYB Stock Data

41.49M
36.75M
4.06%
76.31%
0.88%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW HAVEN